Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte
Oct 24, 2024
auto_awesome
Miguel Forte, CEO of Kiji Therapeutics and President of ISCT, shares his insights on iPSC-MSC therapy for inflammatory diseases. He discusses Kiji's innovative approach to tackling conditions like graft-versus-host disease, inflammatory bowel disease, and psoriasis through advanced clinical trials. The conversation highlights the significance of strategic funding and global collaboration in biotechnology. Forte also reflects on the opportunities presented at ARM's meeting and the importance of networking for future technological advancements.
Kiji Therapeutics aims to revolutionize MSC therapy for inflammatory diseases by utilizing iPSC technology to ensure consistency and cost-effectiveness.
The company is set to start a pivotal clinical trial for GVHD while pursuing collaborations to enhance development and accessibility of cell therapies.
Deep dives
Significance of Kiji Therapeutics
Kiji Therapeutics focuses on addressing the unmet medical needs associated with inflammatory diseases through the use of genetically engineered mesenchymal stromal cells (MSCs). The company aims to professionalize MSC therapy by utilizing induced pluripotent stem cells (iPSCs) to ensure consistency, scalability, and cost-effectiveness in manufacturing. By targeting inflammation through advanced engineering techniques, Kiji aims to produce therapeutic products that effectively modulate the immune system, specifically by secreting high levels of interleukin-10 (IL-10) at sites of inflammation. This strategic approach seeks to enhance the efficacy of MSC therapies beyond current offerings, showing promise in conditions like graft-versus-host disease (GVHD) and inflammatory bowel disease (IBD).
Anticipated Clinical Developments
Kiji Therapeutics is preparing to initiate a proof-of-concept clinical trial in human subjects targeting graft-versus-host disease (GVHD), building on the existing knowledge of unmodified MSCs in this indication. With all necessary studies completed and the Good Manufacturing Practice (GMP) process underway, the company expects to begin patient recruitment by mid-next year. The trial will serve as a critical validation of Kiji's innovative platform and will also allow further exploration into other inflammatory disorders, such as IBD and psoriasis. By leveraging preclinical success in animal models and focusing on patient profiling, Kiji plans to position itself as a leader in next-generation cell therapies.
Collaboration and Global Expansion
Kiji Therapeutics actively engages in global collaboration through established networks in the United States and Asia, recognizing the need for a combined effort in advancing cell and gene therapy. The leadership emphasizes the importance of building relationships, particularly with investors and partners, to facilitate technological development and market access. There's also a strong commitment to ethical considerations, balancing the sustainability of the industry with the objective of providing universal patient access to innovative therapies. This collaborative approach aims to advance the field while ensuring that expectations are managed realistically among stakeholders.
This episode of Cell & Gene: The Podcast was recorded on site during ARM's 2024 Meeting on the Mesa in Phoenix. Tune in to hear Host Erin Harris talk to Miguel Forte, M.D., Ph.D., CEO of Kiji Therapeutics, President of ISCT, and Executive Committee Member of ARM about Kiji's clinical plan and why iPSC-MSC therapy for inflammatory diseases shows great promise. They also cover this year's conference and what to expect during and after the event.